Clinical Trial Detail

NCT ID NCT03363776
Title An Immuno-Therapy Study of Experimental Medication BMS-986277 Given Alone and in Combination With Nivolumab in Epithelial Cancers
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Bristol-Myers Squibb
Indications

prostate cancer

breast cancer

colorectal cancer

ovarian cancer

transitional cell carcinoma

pancreatic cancer

Therapies

BMS-986277

BMS-986277 + Nivolumab

Age Groups: adult senior

No variant requirements are available.